| Budget Amount *help |
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2017: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2016: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2015: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
|
|---|
| Outline of Final Research Achievements |
Based on our Seed and Soil Theory, we conducted some research studies on polymyositis and dermatomyositis (PM / DM) and report here the results of the interleukin (IL) -23 target therapy. As was reported in the patients, serum IL-23 levels were elevated in mice with C protein induced myositis (CIM), a murine model of PM. IL-23p19 was expressed by CD68+ cells in the damaged muscles from the patients. IL-23 were expressed by CD68+ cells in the muscles and draining lymph nodes from CIM mice as well as in chemically injured muscles. Thus, IL-23 production should be associated with the muscle damage. IL-23p19-null mice were resistant to CIM. Administration of anti-IL-23 receptor antibodies ameliorated CIM. When lymph node cells from the CIM mice were transferred into recipients, the myositis was transferred not only to WT but also IL-23p19-null recipients, indicating that IL-23 should activate the autoaggressive T cells. IL-23 should be a promising therapeutic target for PM/DM.
|
